Scandinavian ChemoTech AB Class B (CMOTEC.B) AI Stock Analysis

• Market Cap: kr96.18M
• Dividend Yield: N/A
• Average Volume (3M): 54.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: 132.07%
• EPS Growth: 54.65%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 21,692,312
• 10 Day Avg. Volume: 61,695
• 30 Day Avg. Volume: 54,140
• PEG Ratio: 0.05
• Price to Book (P/B): 6.99
• Price to Sales (P/S): 6.36
• P/FCF Ratio: -3.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: kr5.00 ▲(4.38% Upside)

The score is held back primarily by weak financial performance—heavy losses, ongoing cash burn, and declining equity—despite improving revenue and gross margin. Technicals are a meaningful offset with clear bullish momentum above key moving averages. Valuation remains less supportive due to negative earnings and no stated dividend yield.

Positive Factors

Revenue Growth

The significant increase in revenue growth indicates strong market demand and successful expansion efforts, which can lead to improved financial stability over time.

Gross Margin Improvement

Improved gross margins suggest better cost management and pricing power, enhancing profitability potential and competitive positioning in the market.

Low Debt Levels

The absence of debt reduces financial risk and interest burden, providing the company with greater flexibility to invest in growth opportunities and weather economic downturns.

Negative Factors

Ongoing Operating Losses

Continued operating losses indicate that the company has yet to achieve a sustainable business model, which may require further capital and strategic adjustments to reach profitability.

Negative Cash Flow

Persistent negative cash flow suggests reliance on external funding, which could limit operational flexibility and increase financial risk if not addressed.

Shrinking Equity Base

A declining equity base reflects ongoing losses eroding capital, potentially impacting the company's ability to secure financing and invest in growth initiatives.

Scandinavian ChemoTech AB Class B Business Overview & Revenue Model

Company Description

Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.

How the Company Makes Money

Scandinavian ChemoTech AB generates revenue primarily through the sale and licensing of its proprietary medical technologies and devices designed for cancer treatment. The company's revenue streams include direct sales of its electroporation equipment to healthcare providers and hospitals, as well as potential licensing agreements with other medical technology companies. Additionally, Scandinavian ChemoTech may engage in strategic partnerships or collaborations that contribute to its earnings, leveraging its specialized expertise in electroporation to expand its market reach and enhance its product offerings. These revenue-generating activities are supported by ongoing research and development investments, aimed at continuously improving the efficacy and safety of their treatments.

Scandinavian ChemoTech AB Class B Financial Statement Overview

Summary

Scandinavian ChemoTech AB shows promising revenue growth but continues to face challenges with profitability and cash flow management. The company's financial structure benefits from a lack of debt, reducing financial risk, but operational improvements are needed to achieve sustainable profitability. Continued investment and strategic adjustments may be required to address ongoing losses and cash outflows.

Income Statement

The company demonstrates significant revenue growth, with a sharp increase from SEK 473,000 in 2022 to SEK 6,566,000 in 2024. However, the company has consistently reported negative net income, resulting in negative net profit margins, indicating ongoing losses. Gross profit margins have improved, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows an improvement in the equity ratio, as stockholders' equity remains positive and there is no debt on the balance sheet as of 2024. The return on equity is negative due to persistent losses, but the absence of debt reduces financial risk. The company has a reasonable buffer of cash and short-term investments relative to its liabilities.

Cash Flow

The company's free cash flow has improved from highly negative figures in previous years but remains negative, indicating ongoing cash burn. Operating cash flows have been negative, but financing activities have provided necessary liquidity. The cash flow to net income ratios are negative due to the negative net income and operating cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.85M	6.57M	2.82M	473.00K	49.00K	131.00K
Gross Profit	7.69M	4.78M	1.66M	-55.00K	323.00K	-14.00K
EBITDA	-7.46M	-12.38M	-19.58M	-20.81M	-17.03M	-10.77M
Net Income	-10.68M	-13.72M	-21.09M	-22.75M	-17.74M	-11.66M
Balance Sheet
Total Assets	12.48M	13.38M	14.87M	21.70M	25.81M	15.99M
Cash, Cash Equivalents and Short-Term Investments	517.00K	949.00K	923.00K	5.85M	8.68M	1.49M
Total Debt	0.00	0.00	0.00	0.00	53.00K	2.71M
Total Liabilities	10.29M	7.40M	3.84M	7.71M	1.89M	6.75M
Stockholders Equity	2.19M	5.98M	11.03M	13.99M	23.92M	9.24M
Cash Flow
Free Cash Flow	-9.48M	-13.19M	-18.91M	-19.96M	-22.36M	-10.32M
Operating Cash Flow	-9.48M	-13.14M	-18.23M	-19.63M	-19.18M	-8.49M
Investing Cash Flow	52.00K	-2.00K	-468.00K	-603.00K	-3.33M	-1.83M
Financing Cash Flow	8.09M	13.17M	13.77M	17.26M	29.71M	8.98M

Scandinavian ChemoTech AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CMOTEC.B, the sentiment is Negative. The current price of 4.79 is above the 20-day moving average (MA) of 4.44, above the 50-day MA of 4.47, and above the 200-day MA of 3.30, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 27.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CMOTEC.B.

Scandinavian ChemoTech AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMOTEC.B	52 Neutral	kr96.18M	-11.67	-114.00%	―	132.07%	54.65%
ONCOZ	52 Neutral	kr75.25M	-9.14	-78.79%	―	―	20.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2CUREX	50 Neutral	kr14.31M	-6.76	-304.59%	11.26%	―	―
SPRINT	49 Neutral	kr164.60M	-5.18	-264.12%	―	-17.80%	-11.96%
LARK	43 Neutral	kr46.14M	-1.00	―	8.47%	-94.12%	-25.83%
EXPRS2	41 Neutral	kr60.01M	-0.93	-88.65%	―	8.46%	11.73%